We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+6.48%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.7B
AUM Growth
+$120M
Cap. Flow
-$25.9M
Cap. Flow %
-0.96%
Top 10 Hldgs %
44.18%
Holding
152
New
13
Increased
22
Reduced
27
Closed
8

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$17.5M
2
NVRO
NEVRO CORP.
NVRO
+$15.6M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$14.2M
4
NVS icon
Novartis
NVS
+$11.9M
5
BIIB icon
Biogen
BIIB
+$11.8M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$28.3M
2
MOH icon
Molina Healthcare
MOH
+$18.4M
3
TMO icon
Thermo Fisher Scientific
TMO
+$14.9M
4
PFE icon
Pfizer
PFE
+$11.2M
5
XLV icon
State Street Health Care Select Sector SPDR ETF
XLV
+$10.5M

Sector Composition

Rank Sector Weight
1 Healthcare 91.69%
2 Real Estate 3.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GNMK
126
DELISTED
GenMark Diagnostics, Inc
GNMK
$1.1M 0.04%
93,349
– –
XENE icon
127
Xenon Pharmaceuticals
XENE
$6.2B
$1.1M 0.04%
350,000
– –
AVXS
128
DELISTED
AveXis, Inc. Common Stock
AVXS
$822K 0.03%
+10,000
New +$750K
BLCM
129
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$701K 0.03%
6,000
– –
NVAX icon
130
Novavax
NVAX
$1.22B
$657K 0.02%
28,550
– –
XRN
131
Chiron Real Estate Inc
XRN
$516M
$656K 0.02%
14,680
– –
DCOY
132
Decoy Therapeutics
DCOY
$2.09M
– –
0
– –
ADYX
133
DELISTED
Adynxx Inc
ADYX
$611K 0.02%
27,500
– –
MDRX
134
DELISTED
Veradigm Inc. Common Stock
MDRX
$604K 0.02%
47,300
– –
CYTO
135
DELISTED
Altamira Therapeutics Ltd
CYTO
$554K 0.02%
10
– –
NTLA icon
136
Intellia Therapeutics
NTLA
$1.55B
$448K 0.02%
28,000
-43,842
-61% -$613K
XNCR icon
137
Xencor
XNCR
$1.59B
$422K 0.02%
20,000
– –
RMR icon
138
The RMR Group
RMR
$333M
$362K 0.01%
7,441
– –
CLDX icon
139
Celldex Therapeutics
CLDX
$3.02B
$261K 0.01%
7,053
– –
QHC
140
DELISTED
Quorum Health Corporation
QHC
$98K ﹤0.01%
23,725
– –
LRMR icon
141
Larimar Therapeutics
LRMR
$398M
$47K ﹤0.01%
1,109
– –
ABBV icon
142
AbbVie
ABBV
$455B
$15K ﹤0.01%
213
+57
+37% +$3.83K
EW icon
143
Edwards Lifesciences
EW
$50B
– –
-167,700
Closed -$5.26M
GRFS
144
Grifois
GRFS
$5.58B
– –
-166,000
Closed -$3.13M
HALO icon
145
Halozyme
HALO
$9.88B
– –
-200,000
Closed -$2.59M
MOH icon
146
Molina Healthcare
MOH
$10.2B
– –
-402,541
Closed -$18.4M
XLV icon
147
State Street Health Care Select Sector SPDR ETF
XLV
$42.2B
– –
-140,600
Closed -$10.5M
ONC
148
BeOne Medicines Ltd
ONC
$33.4B
– –
-87,531
Closed -$3.21M
FWP
149
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
– –
-17,548
Closed -$2.64M
CCP
150
DELISTED
Care Capital Properties, Inc.
CCP
– –
-345,022
Closed -$9.27M
2 3 4 5
6

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2017 Portfolio in Review

As of Q2 2017, Tekla Capital Management held 152 positions worth $2.7B, up 4.7% from $2.58B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Tekla Capital Management's Q2 2017 filing shows 13 new, 22 increased, 27 reduced and 8 closed positions. Its largest new stake was NEVRO CORP.: 194,621 shares worth $14.5M. The largest sale was Vertex Pharmaceuticals, an estimated $28.3M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 91% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q2 2017 buy was NEVRO CORP.: 194,621 shares worth $14.5M.
  • Tekla Capital Management added most to Merck in Q2 2017, an estimated $17.5M increase.
  • Tekla Capital Management's biggest Q2 2017 reduction was Vertex Pharmaceuticals, cutting an estimated $28.3M.
  • Tekla Capital Management fully exited Molina Healthcare in Q2 2017, selling an estimated $18.4M.
  • Tekla Capital Management's ten largest holdings make up 44% of its $2.7B portfolio in Q2 2017.
  • Tekla Capital Management opened 13 new positions and closed 8 in Q2 2017.
  • Tekla Capital Management's portfolio value rose 4.7% quarter-over-quarter to $2.7B.

Based on Tekla Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.